SLSN Q1 2026 Earnings Call Summary

Revenue: $13 million, down from $14.6 million in Q1 2025, attributed to delays in shipments due to operational challenges.
Gross Margin: Increased by 300 basis points to 26%, driven by improved labor efficiency and reduced product quality-related waste.
Net Income: Reported a loss of $0.8 million, compared to net income of $0.08 million in the prior year.
Adjusted EBITDA: Loss of $107,000, down from a positive $609,000 in Q1 2025.
Shipped and Open Orders: Totaled $47 million, indicating a healthy demand outlook despite current revenue challenges.

Transform and Transcend Initiative: Launched in late 2025, aimed at enhancing operational execution and transitioning from a traditional CDMO model to a strategic innovation partner.
Operational Changes: Implemented a new shift structure and invested in employee training to improve productivity and reduce downtime.
New Technologies: Announced the launch of two proprietary technologies, Chromalum and WHSPR, aimed at expanding product offerings in the SPF-infused beauty market.
Co-Marketing Programs: Successfully completed four initiatives with brand partners, enhancing strategic relationships and product performance.

Revenue Expectations: Management expects a return to a more normalized revenue environment as operational improvements take effect throughout 2026.
Profitability Goals: Reiterated a 30% floor for gross profit margins and aims to achieve double-digit EBITDA margins by year-end, driven by operational efficiencies and facility consolidation savings.

Operational Delays: The first quarter's revenue decline was primarily due to On-Time and In-Full (OTIF) performance issues, which management is actively addressing.
Market Conditions: While there is ongoing interest in products, the company is navigating a year of rationalized performance, reflecting broader market conditions rather than a lack of demand.
Investment Pressure: Initial investments in operational changes have resulted in near-term profitability pressure, which may concern some investors.

Interest in Products: Management clarified that the decline in revenue does not indicate reduced interest in their products but is a result of operational adjustments.
Future Revenue: Analysts expressed optimism regarding future revenue, with management confirming expectations for improved performance as operational issues are resolved.
Order Backlog Clarification: The $47 million figure represents a combination of shipped orders and open orders expected to be fulfilled within the year, providing a positive outlook for revenue.

Overall, while Solesence faced challenges in Q1 2026, management remains confident in their strategic initiatives and long-term growth potential.

SLSN — Solesence, Inc. Common Stock